Skip to Main Content

A Study of RVT-1401 in Myasthenia Gravis (MG) Patients

Conditions

Diseases of the Nervous System

Phase IIA

What is the purpose of this trial?

Brief Summary:

The purpose of the current study is to assess safety/tolerability and key pharmacodynamic (PD) effects that are considered to be associated with clinical benefit (reduction of total IgG and anti-AChR-IgG) in Myasthenia Gravis patients following treatment with RVT-1401 (also known as IMVT-1401) compared to placebo

  • Trial with
    Immunovant Sciences GmbH
  • Start Date
    09/24/2019
  • End Date
    12/30/2019
Trial Image

For more information about this study, contact:

Bailey Munro Sheldon

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    11/19/2019
  • Study HIC
    #2000025712